000163053 001__ 163053
000163053 005__ 20251009133841.0
000163053 0247_ $$2doi$$a10.3390/jcm14176173
000163053 0248_ $$2sideral$$a145515
000163053 037__ $$aART-2025-145515
000163053 041__ $$aeng
000163053 100__ $$aEsteban-Floría, Olivia
000163053 245__ $$aEfficacy and Safety of Faricimab in Diabetic Macular Edema: Real-World Outcomes in Treatment-Naïve and Previously Treated Eyes
000163053 260__ $$c2025
000163053 5060_ $$aAccess copy available to the general public$$fUnrestricted
000163053 5203_ $$aBackground: The objective of this study was to assess the efficacy and safety of faricimab in diabetic macular edema (DME) in patients who were treatment-naïve or previously treated in a real-world setting. Methods: This was a retrospective, observational, single-center study that included 105 eyes from 79 patients diagnosed with DME and treated with intravitreal faricimab between January 2024 and January 2025. Patients were categorized into two groups according to their treatment history, namely treatment-naïve eyes and eyes previously treated (switch group). Functional (best-corrected visual acuity, BCVA) and anatomical (central foveal thickness, CFT; macular volume, MV) outcomes were assessed. The safety of faricimab was evaluated from changes in intraocular pressure and the occurrence of adverse events. Results: BCVA improved significantly in both groups, with a mean gain of +0.16 in treatment-naïve eyes and +0.10 in switch eyes. The mean reduction in CFT was −53.7 µm in the naïve group and −37.8 µm in the switch group. MV decreased by −0.4 mm3 overall, with significant reductions in both groups. No adverse events were reported, confirming the safety of faricimab in routine clinical practice. Conclusions: Faricimab showed significant improvements in functional and anatomical outcomes in patients with DME, regardless of the use of previous anti-VEGF therapies. These findings support the effectiveness and safety of faricimab in a real-world clinical setting and reinforce its potential as a valuable treatment option for DME.
000163053 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttps://creativecommons.org/licenses/by/4.0/deed.es
000163053 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000163053 700__ $$aMateo, Javier$$uUniversidad de Zaragoza
000163053 700__ $$aLara, Javier
000163053 700__ $$aBartolomé, Isabel
000163053 700__ $$aHerrero, Inmaculada
000163053 700__ $$aPérez, María A.
000163053 700__ $$aCabello, Concepción
000163053 700__ $$aHonrubia, Ana
000163053 700__ $$0(orcid)0000-0003-0349-9997$$aPinilla, Isabel$$uUniversidad de Zaragoza
000163053 700__ $$0(orcid)0000-0001-9876-5850$$aAscaso, Javier$$uUniversidad de Zaragoza
000163053 7102_ $$11013$$2646$$aUniversidad de Zaragoza$$bDpto. Cirugía$$cÁrea Oftalmología
000163053 773__ $$g14, 17 (2025), 6173 [9 pp.]$$pJ. clin.med.$$tJournal of Clinical Medicine$$x2077-0383
000163053 8564_ $$s243959$$uhttps://zaguan.unizar.es/record/163053/files/texto_completo.pdf$$yVersión publicada
000163053 8564_ $$s2585250$$uhttps://zaguan.unizar.es/record/163053/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000163053 909CO $$ooai:zaguan.unizar.es:163053$$particulos$$pdriver
000163053 951__ $$a2025-10-09-13:25:56
000163053 980__ $$aARTICLE